Acar J F, Goldstein F W, Kitzis M D
Department of Medical Microbiology and Infectious Diseases, Hôpital Saint-Joseph, Paris, France.
J Antimicrob Chemother. 1993 Jan;31 Suppl A:23-8. doi: 10.1093/jac/31.suppl_a.23.
Among 325 fresh isolates of bacteria from 153 hospital patients with serious infections, 142 were susceptible to piperacillin, 129 were resistant and a further 54 exhibited a marked inoculum effect. Tazobactam restored the susceptibility of resistant isolates of Staphylococcus aureus and Staphylococcus epidermidis (except methicillin-resistant isolates), Haemophilus influenzae, Moraxella catarrhalis, Acinetobacter spp. and Bacteroides fragilis. Among 87 Enterobacteriaceae that were resistant to piperacillin, or showed an inoculum effect, 78 (89%) were restored to susceptibility by tazobactam. Pseudomonas spp. resistant to piperacillin were mostly resistant to the combination.
在从153例患有严重感染的住院患者中分离出的325株新鲜细菌中,142株对哌拉西林敏感,129株耐药,另有54株表现出明显的接种量效应。他唑巴坦恢复了金黄色葡萄球菌和表皮葡萄球菌(耐甲氧西林菌株除外)、流感嗜血杆菌、卡他莫拉菌、不动杆菌属和脆弱拟杆菌耐药菌株的敏感性。在87株对哌拉西林耐药或表现出接种量效应的肠杆菌科细菌中,78株(89%)经他唑巴坦治疗后恢复了敏感性。对哌拉西林耐药的假单胞菌属大多对联合用药耐药。